These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 23365855)
1. Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology. Mera TO; Burack MA; Giuffrida JP Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():154-7. PubMed ID: 23365855 [TBL] [Abstract][Full Text] [Related]
2. Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease. Mera TO; Burack MA; Giuffrida JP J Parkinsons Dis; 2013 Jan; 3(3):399-407. PubMed ID: 23948993 [TBL] [Abstract][Full Text] [Related]
3. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation. Li MH; Mestre TA; Fox SH; Taati B J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914 [TBL] [Abstract][Full Text] [Related]
4. Motion sensor dyskinesia assessment during activities of daily living. Pulliam CL; Burack MA; Heldman DA; Giuffrida JP; Mera TO J Parkinsons Dis; 2014; 4(4):609-15. PubMed ID: 25208729 [TBL] [Abstract][Full Text] [Related]
5. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. Zesiewicz TA; Sullivan KL; Hauser RA Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536 [TBL] [Abstract][Full Text] [Related]
6. Objective measurement of dyskinesia in Parkinson's disease using a force plate. Chung KA; Lobb BM; Nutt JG; McNames J; Horak F Mov Disord; 2010 Apr; 25(5):602-8. PubMed ID: 20213818 [TBL] [Abstract][Full Text] [Related]
7. Movement parameters that distinguish between voluntary movements and levodopa-induced dyskinesia in Parkinson's disease. Keijsers NL; Horstink MW; Gielen SC Hum Mov Sci; 2003 Feb; 22(1):67-89. PubMed ID: 12623181 [TBL] [Abstract][Full Text] [Related]
8. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study. Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722 [TBL] [Abstract][Full Text] [Related]
9. Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks. Keijsers NL; Horstink MW; van Hilten JJ; Hoff JI; Gielen CC Mov Disord; 2000 Nov; 15(6):1104-11. PubMed ID: 11104192 [TBL] [Abstract][Full Text] [Related]
10. Quantitative motor assessment of dyskinesias in Parkinson's disease. Schaeffer E; Maetzler W; Liepelt-Scarfone I; Sass C; Reilmann R; Berg D J Neural Transm (Vienna); 2015 Sep; 122(9):1271-8. PubMed ID: 25712401 [TBL] [Abstract][Full Text] [Related]
11. Force overflow and levodopa-induced dyskinesias in Parkinson's disease. Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119 [TBL] [Abstract][Full Text] [Related]
12. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia. Kipfer S; Stephan MA; Schüpbach WM; Ballinari P; Kaelin-Lang A Arch Neurol; 2011 Aug; 68(8):1037-9. PubMed ID: 21825240 [TBL] [Abstract][Full Text] [Related]
13. Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features. Li MH; Mestre TA; Fox SH; Taati B Parkinsonism Relat Disord; 2018 Aug; 53():42-45. PubMed ID: 29748112 [TBL] [Abstract][Full Text] [Related]
14. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia. Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335 [TBL] [Abstract][Full Text] [Related]
15. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia? Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690 [TBL] [Abstract][Full Text] [Related]
16. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients. Dias CMV; Leal DAB; Brys I Int J Neurosci; 2023 Dec; 133(12):1319-1325. PubMed ID: 35603453 [No Abstract] [Full Text] [Related]
17. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study. Liu G; Chen H; Su D; Wang D; Zhang M; Wang X; Wang Z; Yang Y; Jiang Y; Ma H; Feng T Neurol Sci; 2020 Jan; 41(1):111-118. PubMed ID: 31446577 [TBL] [Abstract][Full Text] [Related]
18. Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning. Loo RTJ; Tsurkalenko O; Klucken J; Mangone G; Khoury F; Vidailhet M; Corvol JC; Krüger R; Glaab E; Parkinsonism Relat Disord; 2024 Sep; 126():107054. PubMed ID: 38991633 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. Putterman DB; Munhall AC; Kozell LB; Belknap JK; Johnson SW J Pharmacol Exp Ther; 2007 Oct; 323(1):277-84. PubMed ID: 17660384 [TBL] [Abstract][Full Text] [Related]
20. Dyskinesia estimation during activities of daily living using wearable motion sensors and deep recurrent networks. Hssayeni MD; Jimenez-Shahed J; Burack MA; Ghoraani B Sci Rep; 2021 Apr; 11(1):7865. PubMed ID: 33846387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]